{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:09:25Z","timestamp":1662703765070},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T00:00:00Z","timestamp":1391126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s00059-013-4049-y","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T03:18:02Z","timestamp":1390965482000},"page":"178-185","source":"Crossref","is-referenced-by-count":1,"title":["Differenzialtherapie der koronaren Herzkrankheit"],"prefix":"10.1007","volume":"39","author":[{"given":"H.","family":"Wienbergen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hambrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,31]]},"reference":[{"key":"4049_CR1","unstructured":"Statistisches Bundesamt (2012) Todesursachen in Deutschland 2012, Fachserie 12, Reihe 4. http:\/\/www.destatis.de"},{"key":"4049_CR2","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33(13):1635\u20131701","journal-title":"Eur Heart J"},{"key":"4049_CR3","first-page":"CD003041","volume":"Rev","author":"Critchley","year":"2004","unstructured":"Critchley J, Capewell S (2004) Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev (1):CD003041","journal-title":"Cochrane Database Syst"},{"key":"4049_CR4","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"Montalescot","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S et al (2013) ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949\u20133003","journal-title":"Eur Heart J"},{"key":"4049_CR5","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2009.07.022","volume":"54","author":"Meyers","year":"2009","unstructured":"Meyers DG, Neuberger JS, He J (2009) Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis. J Am Coll Cardiol 54(14):1249\u20131255","journal-title":"J Am Coll Cardiol"},{"key":"4049_CR6","doi-asserted-by":"crossref","unstructured":"Schmucker J, Wienbergen H, Seide S et al (2013) Smoking ban in public areas is associated with a reduced incidence of hospital admissions due to ST-elevation myocardial infarctions in non-smokers. Results from the BREMEN STEMI REGISTRY. Eur J Prev Cardiol [Epub ahead of print]","DOI":"10.1177\/2047487313483610"},{"key":"4049_CR7","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehq236","volume":"31","author":"Piepoli","year":"2010","unstructured":"Piepoli MF, Corra U, Benzer W et al (2010) Secondary prevention through cardiac rehabilitation: physical activity counselling and exercise training: key components of the position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur Heart J 31(16):1967\u20131974","journal-title":"Eur Heart J"},{"key":"4049_CR8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJM200002173420702","volume":"342","author":"Hambrecht","year":"2000","unstructured":"Hambrecht R, Wolf A, Gielen S et al (2000) Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 342(7):454\u2013460","journal-title":"N Engl J Med"},{"key":"4049_CR9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/01.CIR.0000121360.31954.1F","volume":"109","author":"Hambrecht","year":"2004","unstructured":"Hambrecht R, Walther C, Moebius-Winkler S et al (2004) Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 109(11):1371\u20131378","journal-title":"Circulation"},{"key":"4049_CR10","first-page":"CD001800","volume":"Rev","author":"Heran","year":"2011","unstructured":"Heran BS, Chen JM, Ebrahim S et al (2011) Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev (7):CD001800","journal-title":"Cochrane Database Syst"},{"key":"4049_CR11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/01.CIR.99.6.779","volume":"99","author":"Lorgeril","year":"1999","unstructured":"Lorgeril M de, Salen P, Martin JL et al (1999) Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99(6):779\u2013785","journal-title":"Circulation"},{"key":"4049_CR12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","volume":"368","author":"Estruch","year":"2013","unstructured":"Estruch R, Ros E, Salas-Salvado J et al (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368(14):1279\u20131290","journal-title":"N Engl J Med"},{"key":"4049_CR13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494\u2013502","journal-title":"N Engl J Med"},{"key":"4049_CR14","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs289","volume":"33","author":"Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33(20):2569\u20132619","journal-title":"Eur Heart J"},{"key":"4049_CR15","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001\u20132015","journal-title":"N Engl J Med"},{"key":"4049_CR16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045\u20131057","journal-title":"N Engl J Med"},{"key":"4049_CR17","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","unstructured":"Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 32(23):2999\u20133054","journal-title":"Eur Heart J"},{"key":"4049_CR18","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352(14):1425\u20131435","journal-title":"N Engl J Med"},{"key":"4049_CR19","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","volume":"295","author":"Nissen","year":"2006","unstructured":"Nissen SE, Nicholls SJ, Sipahi I et al (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295(13):1556\u20131565","journal-title":"JAMA"},{"key":"4049_CR20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199907083410202","volume":"341","author":"Pitt","year":"1999","unstructured":"Pitt B, Waters D, Brown WV et al (1999) Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 341(2):70\u201376","journal-title":"N Engl J Med"},{"key":"4049_CR21","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670\u20131681","journal-title":"Lancet"},{"key":"4049_CR22","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa0907272","volume":"362","author":"Patel","year":"2010","unstructured":"Patel MR, Peterson ED, Dai D et al (2010) Low diagnostic yield of elective coronary angiography. N Engl J Med 362(10):886\u2013895","journal-title":"N Engl J Med"},{"key":"4049_CR23","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2013) Nationale VersorgungsLeitlinie Chronische KHK, 2. Aufl. Version 1. http:\/\/www.versorgungsleitlinien.de"},{"key":"4049_CR24","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.1161\/CIRCULATIONAHA.113.000821","volume":"127","author":"Hambrecht","year":"2013","unstructured":"Hambrecht R, Berra K, Calfas KJ (2013) Cardiology patient page. Managing your angina symptoms with nitroglycerin: what about exercise? Circulation 127(22):e642\u2013e645","journal-title":"Circulation"},{"key":"4049_CR25","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/CIRCULATIONAHA.110.981407","volume":"123","author":"Muenzel","year":"2011","unstructured":"Muenzel T, Daiber A, Gori T (2011) Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 123(19):2132\u20132144","journal-title":"Circulation"},{"key":"4049_CR26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.coph.2012.12.008","volume":"13","author":"Muenzel","year":"2013","unstructured":"Muenzel T, Gori T (2013) Nitrate therapy and nitrate tolerance in patients with coronary artery disease. Curr Opin Pharmacol 13(2):251\u2013259","journal-title":"Curr Opin Pharmacol"},{"key":"4049_CR27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jacc.2006.10.074","volume":"49","author":"Thomas","year":"2007","unstructured":"Thomas GR, DiFabio JM, Gori T et al (2007) Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 49(12):1289\u20131295","journal-title":"J Am Coll Cardiol"},{"key":"4049_CR28","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.1988.03410140100032","volume":"260","author":"Yusuf","year":"1988","unstructured":"Yusuf S, Wittes J, Friedman L (1988) Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 260(14):2088\u20132093","journal-title":"JAMA"},{"key":"4049_CR29","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","volume":"308","author":"Bangalore","year":"2012","unstructured":"Bangalore S, Steg G, Deedwania P et al (2012) Beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308(13):1340\u20131349","journal-title":"JAMA"},{"key":"4049_CR30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.amjmed.2008.09.043","volume":"122","author":"Bangalore","year":"2009","unstructured":"Bangalore S, Parkar S, Messerli FH (2009) Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med 122(4):356\u2013365","journal-title":"Am J Med"},{"key":"4049_CR31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(08)61172-1","volume":"372","author":"Reil","year":"2008","unstructured":"Reil JC, Boehm M (2008) BEAUTIFUL results \u2013 the slower, the better? Lancet 372(9641):779\u2013780","journal-title":"Lancet"},{"key":"4049_CR32","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"Tardif","year":"2005","unstructured":"Tardif JC, Ford I, Tendera M et al (2005) Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26(23):2529\u20132536","journal-title":"Eur Heart J"},{"key":"4049_CR33","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","volume":"30","author":"Tardif","year":"2009","unstructured":"Tardif JC, Ponikowski P, Kahan T (2009) Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 30(5):540\u2013548","journal-title":"Eur Heart J"},{"key":"4049_CR34","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","volume":"30","author":"Fox","year":"2009","unstructured":"Fox K, Ford I, Steg P et al (2009) Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 30(19):2337\u20132345","journal-title":"Eur Heart J"},{"key":"4049_CR35","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00392-007-0612-y","volume":"97","author":"Hasenfuss","year":"2008","unstructured":"Hasenfuss G, Maier LS (2008) Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol 97(4):222\u2013226","journal-title":"Clin Res Cardiol"},{"key":"4049_CR36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"Chaitman","year":"2004","unstructured":"Chaitman BR, Pepine CJ, Parker JO et al (2004) Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291(3):309\u2013316","journal-title":"JAMA"},{"key":"4049_CR37","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","volume":"297","author":"Morrow","year":"2007","unstructured":"Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al (2007) Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 297(16):1775\u20131783","journal-title":"JAMA"},{"key":"4049_CR38","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","volume":"119","author":"Morrow","year":"2009","unstructured":"Morrow DA, Scirica BM, Chaitman BR et al (2009) Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 119(15):2032\u20132039","journal-title":"Circulation"},{"key":"4049_CR39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","volume":"27","author":"Timmis","year":"2006","unstructured":"Timmis AD, Chaitman BR, Crager M (2006) Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 27(1):42\u201348","journal-title":"Eur Heart J"},{"key":"4049_CR40","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","volume":"61","author":"Kosiborod","year":"2013","unstructured":"Kosiborod M, Arnold SV, Spertus JA et al (2013) Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol 61(20):2038\u20132045","journal-title":"J Am Coll Cardiol"},{"key":"4049_CR41","unstructured":"RITA-2 trial participants (1997) Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 350(9076):461\u2013468"},{"key":"4049_CR42","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK et al (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(15):1503\u20131516","journal-title":"N Engl J Med"},{"key":"4049_CR43","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1161\/CIRCULATIONAHA.107.743963","volume":"117","author":"Shaw","year":"2008","unstructured":"Shaw LJ, Berman DS, Maron DJ et al (2008) Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117(10):1283\u20131291","journal-title":"Circulation"},{"key":"4049_CR44","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","volume":"360","author":"BARI","year":"2009","unstructured":"BARI 2D Study Group, Frye RL, August P et al (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360(24):2503\u20132515","journal-title":"N Engl J Med"},{"key":"4049_CR45","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0140-6736(10)60168-7","volume":"375","author":"Pfisterer","year":"2010","unstructured":"Pfisterer ME, Zellweger MJ, Gersh BJ (2010) Management of stable coronary artery disease. Lancet 375(9716):763\u2013772","journal-title":"Lancet"},{"key":"4049_CR46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11936-012-0214-5","volume":"15","author":"Mecklai","year":"2013","unstructured":"Mecklai A, Bangalore S, Hochman J (2013) How and when to decide on revascularization in stable ischemic heart disease. Curr Treat Options Cardiovasc Med 15(1):79\u201392","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"4049_CR47","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMoa1205361","volume":"367","author":"De","year":"2012","unstructured":"De Bruyne B, Pijls NH, Kalesan B et al (2012) Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367(11):991\u20131001","journal-title":"N Engl J Med"},{"key":"4049_CR48","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1161\/01.CIR.0000146338.62813.E7","volume":"110","author":"Jasti","year":"2004","unstructured":"Jasti V, Ivan E, Yalamanchili V et al (2004) Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis. Circulation 110(18):2831\u20132836","journal-title":"Circulation"},{"key":"4049_CR49","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4244\/EIJV4I4A89","volume":"4","author":"Barlis","year":"2009","unstructured":"Barlis P, Schmitt JM (2009) Current and future developments in intracoronary optical coherence tomography imaging. EuroIntervention 4(4):529\u2013533","journal-title":"EuroIntervention"},{"key":"4049_CR50","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq172","volume":"31","author":"Wijns","year":"2010","unstructured":"Wijns W, Kolh P, Danchin N et al (2010) Guidelines on myocardial revascularization. Eur Heart J 31(20):2501\u20132555","journal-title":"Eur Heart J"},{"key":"4049_CR51","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa0804626","volume":"360","author":"Serruys","year":"2009","unstructured":"Serruys PW, Morice MC, Kappetein AP et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961\u2013972","journal-title":"N Engl J Med"},{"key":"4049_CR52","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/eurheartj\/ehr213","volume":"32","author":"Kappetein","year":"2011","unstructured":"Kappetein AP, Feldman TE, Mack MJ et al (2011) Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and\/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 32(17):2125\u20132134","journal-title":"Eur Heart J"},{"key":"4049_CR53","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(13)60141-5","volume":"381","author":"Mohr","year":"2013","unstructured":"Mohr FW, Morice MC, Kappetein AP et al (2013) Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 381(9867):629\u2013638","journal-title":"Lancet"},{"key":"4049_CR54","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1211585","volume":"367","author":"Farkouh","year":"2012","unstructured":"Farkouh ME, Domanski M, Sleeper LA et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367(25):2375\u20132384","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-013-4049-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-013-4049-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-013-4049-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T23:35:33Z","timestamp":1565134533000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-013-4049-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,31]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["4049"],"URL":"https:\/\/doi.org\/10.1007\/s00059-013-4049-y","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,31]]}}}